Chemours Company (The) (NYSE:CC) SVP David C. Shelton sold 19,000 shares of the firm’s stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $53.68, for a total value of $1,019,920.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

David C. Shelton also recently made the following trade(s):

  • On Thursday, August 31st, David C. Shelton sold 13,337 shares of Chemours Company (The) stock. The shares were sold at an average price of $48.48, for a total value of $646,577.76.

Shares of Chemours Company (NYSE CC) opened at 54.67 on Friday. The firm has a 50-day moving average price of $51.45 and a 200-day moving average price of $51.45. Chemours Company has a 1-year low of $14.41 and a 1-year high of $54.83. The stock has a market capitalization of $10.10 billion, a PE ratio of 35.78 and a beta of 3.59.

Chemours Company (The) (NYSE:CC) last issued its earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.02. The business had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.49 billion. Chemours Company (The) had a return on equity of 122.97% and a net margin of 4.96%. The company’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.27 EPS. On average, equities research analysts forecast that Chemours Company will post $3.51 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Thursday, August 17th were paid a dividend of $0.03 per share. This represents a $0.12 dividend on an annualized basis and a dividend yield of 0.22%. The ex-dividend date was Tuesday, August 15th. Chemours Company (The)’s dividend payout ratio (DPR) is 8.11%.

ILLEGAL ACTIVITY NOTICE: “David C. Shelton Sells 19,000 Shares of Chemours Company (The) (CC) Stock” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/07/david-c-shelton-sells-19000-shares-of-chemours-company-the-cc-stock.html.

A number of equities research analysts recently weighed in on the company. UBS AG reaffirmed a “sell” rating and set a $36.00 price objective (up previously from $35.00) on shares of Chemours Company (The) in a research report on Wednesday, June 14th. Zacks Investment Research downgraded Chemours Company (The) from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. J P Morgan Chase & Co raised their price objective on Chemours Company (The) to $55.00 and gave the company an “overweight” rating in a research report on Friday, August 4th. Argus reaffirmed a “buy” rating and set a $55.00 price objective (up previously from $50.00) on shares of Chemours Company (The) in a research report on Thursday, August 10th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $50.00 price objective (up previously from $48.00) on shares of Chemours Company (The) in a research report on Thursday, July 13th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $52.75.

Several hedge funds have recently modified their holdings of the company. Acrospire Investment Management LLC raised its stake in shares of Chemours Company (The) by 3.4% during the 2nd quarter. Acrospire Investment Management LLC now owns 3,076 shares of the specialty chemicals company’s stock worth $117,000 after buying an additional 100 shares in the last quarter. Charter Trust Co. raised its stake in shares of Chemours Company (The) by 2.1% during the 2nd quarter. Charter Trust Co. now owns 5,720 shares of the specialty chemicals company’s stock worth $217,000 after buying an additional 120 shares in the last quarter. Neuberger Berman Group LLC raised its stake in shares of Chemours Company (The) by 1.5% during the 1st quarter. Neuberger Berman Group LLC now owns 9,579 shares of the specialty chemicals company’s stock worth $369,000 after buying an additional 141 shares in the last quarter. Cypress Capital Management LLC raised its stake in shares of Chemours Company (The) by 0.5% during the 2nd quarter. Cypress Capital Management LLC now owns 31,393 shares of the specialty chemicals company’s stock worth $1,190,000 after buying an additional 155 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in shares of Chemours Company (The) by 0.6% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 26,921 shares of the specialty chemicals company’s stock worth $1,021,000 after buying an additional 167 shares in the last quarter. 72.90% of the stock is owned by institutional investors and hedge funds.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Insider Buying and Selling by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Stock Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related stocks with our FREE daily email newsletter.